BriaCell to Present New Clinical Data at the 2022 San Antonio Breast Cancer Symposium® December 6th and 7th

PHILADELPHIA and VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce that its lead product candidate, Bria-IMT™, will be featured in three posters during the 2022 San Antonio Breast Cancer Symposium® taking place December 6-10, 2022 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.

“Our mission is to find solutions for advanced breast cancer patients who do not respond to current treatments. We are thrilled for the opportunity to share our clinical findings with clinicians who treat similar, difficult-to-treat patients,” stated Dr. Bill Williams, BriaCell’s President & CEO.

All poster presentations will be held at Hall 1, Henry B. Gonzalez Convention Center, 900 E. Market Street, San Antonio, TX 78205 U.S.A. Details on the poster presentations are as follows:

Poster ID: P1-05-28
Date: Tuesday, December 6, 2022
Time: 5:00 PM – 6:15 PM

Poster ID: P3-07-12
Poster ID: P3-06-08
Date: Wednesday, December 7, 2022
Time: 5:00 PM – 6:15 PM

Following the presentations, copies of the posters will be posted on https://briacell.com/scientific-publications/.

About BriaCell Therapeutics Corp.

BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/.

Safe Harbor

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company’s profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

Neither Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

Company Contact:

William V. Williams, MD
President & CEO
1-888-485-6340
[email protected] 

Media Relations:

Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
[email protected]

Investor Relations Contact:

CORE IR
[email protected]

 



XPO Logistics Honors David Frazier as First Driver in Company History to Achieve Four Million Accident-Free Miles

GREENWICH, Conn., Sept. 28, 2022 (GLOBE NEWSWIRE) — XPO Logistics (NYSE: XPO), a North American leader in less-than-truckload (LTL) freight transportation, today announced that long-time truck driver David Frazier has exceeded four million accident-free miles in his LTL career — the highest driver safety record in XPO’s history. The company tracks accident-free miles as part of its Road to Zero driver safety program.

Frazier began driving LTL tractors in 1987 with Con-way, which was acquired by XPO in 2015. His groundbreaking four millionth mile was documented at the company’s terminal in Kernersville, North Carolina, where he has been based for over 34 years. It can take a professional truck driver nine years on average to cover one million miles, making Frazier’s accomplishment even more remarkable, given his tenure.

Mario Harik, president, less-than-truckload, XPO Logistics, said, “David is a legend in our network and a role model in every respect, particularly when it comes to safety procedures. Our drivers have watched him operate thousands of times and learned to always do things the right way. It’s a privilege to share his milestone with the industry.”

The company has honored Frazier with a team celebration in Kernersville attended by district, region and corporate leaders. He also received the keys to a brand new XPO tractor with a customized cab design that displays his name and record achievement.

XPO is one of the largest providers of LTL transportation in North America, with a network of 294 terminals and approximately 13,000 professional truck drivers. The company is investing in expanding its LTL customer service capacity with additional drivers, dockworkers, tractors, trailers, terminals and doors. 

About XPO Logistics

XPO Logistics, Inc. (NYSE: XPO) is a leading provider of freight transportation services, primarily less-than-truckload (LTL) and truck brokerage. XPO uses its proprietary technology, including the cutting-edge XPO Connect® automated freight marketplace, to move goods efficiently through supply chains. The company’s global network serves 50,000 shippers with approximately 749 locations and 43,000 employees, and is headquartered in Greenwich, Conn., USA. Visit xpo.com and europe.xpo.com for more information, and connect with XPO on FacebookTwitterLinkedInInstagram and YouTube.

Media Contact

Karina Frayter
+1-203-484-8303
[email protected]



VF Corporation Introduces Fiscal Year 2027 Long-term Strategic Plan and Financial Targets With Revised Outlook for Fiscal Year 2023

VF Corporation Introduces Fiscal Year 2027 Long-term Strategic Plan and Financial Targets With Revised Outlook for Fiscal Year 2023

  • VF introduces the fiscal year 2027 (FY27) long-term strategic growth plan, which outlines the Company’s plan to drive value for shareholders
  • FY27 financial targets include:

    • Revenue five-year compounded annual growth rate (CAGR) up mid- to high single digit % (in constant dollars).
    • Operating margin of approximately 15% by FY27, reflecting both gross margin expansion and SG&A leverage.
    • Earnings per share (EPS) to grow at a five-year CAGR of high single to low double-digit %.
    • Cash available to return to shareholders through dividends and share repurchases of approximately $7 billion (cumulative between fiscal year 2023 (FY23) and FY27) with Organic Total Shareholder Return (TSR) between a low double-digit % and low teens % CAGR.
  • FY23 outlook revised; revenue expected to be up about 5% to 6% and adjusted EPS expected to be in the range of $2.60 to $2.70.

DENVER–(BUSINESS WIRE)–
VF Corporation (NYSE: VFC), a leading portfolio of active-lifestyle brands including Vans®, The North Face®, Timberland® and Dickies®, today is hosting its 2022 Investor Day in Denver, Colorado. In connection with the event, the company is introducing a FY27 long-term strategic growth plan and financial targets.

“Our new five-year growth plan demonstrates how we will leverage VF’s proven strengths and distinct model to deliver superior returns to shareholders over the long term,” said VF Chairman, President and CEO, Steve Rendle. “The global economic environment has dramatically changed since we held our last Investor Day in late 2019. Despite significant disruptions during the past three years, VF has successfully navigated the challenges to become a more agile and focused enterprise that is advancing a clear vision to be the world’s most dynamic portfolio of iconic, deeply loved, active-lifestyle brands.”

“While economic uncertainties persist, we are actively addressing challenges within our business, and we remain confident in our ability to generate consistent, sustainable growth across our brand portfolio over the long term. We will continue to deepen our engagement with consumers, expand into new categories and markets, leverage our powerful business platforms, and lean on the seasoned leaders and talented teams who are driving our strategies. VF and our brands remain well-positioned to continue our journey of broad-based growth and success.”

Long-Term Strategic Growth Plan

At the event, members of VF’s executive leadership team will present a detailed overview of the Company’s strategies, which outline its commitment to driving consistent, sustainable and profitable growth. The strategic choices include:

  • Find and Amplify Consumer Tailwinds:​ The Company will innovate within its existing brand portfolio while also strategically expanding into adjacencies that complement its current brands and tap into consumer growth spaces.
  • Build Brands on Multiple Growth Horizons:​ The Company will gain market share by building and managing brands at different stages of growth across the portfolio, as well as through M&A and business development to benefit both individual brands and the enterprise.
  • Leverage Platforms for Speed to Scale and Efficiency: The Company will leverage its strategic platforms, which provide a unique set of large-scale capabilities to enable its brands to connect more directly with consumers and operate more efficiently, including consumer data and analytics, direct-to-consumer (DTC) centric supply chain, digitally enabled seamless consumer experience and international platforms.
  • Resource for Portfolio Agility and Performance: The Company will continue to manage its business with organizational agility and dynamically allocate capital and deploy people to drive its highest-priority strategic and growth-focused initiatives​.

FY27 Financial Targets

  • Revenue through FY27 is expected to grow at a five-year CAGR of mid- to high single digit % (in constant dollars) with all brands, regions and channels contributing to growth over that time.
    • The North Face® brand revenue five-year CAGR expected to be up high single to low double-digit % (in constant dollars).
    • Vans® brand revenue five-year CAGR expected to be up mid-single digit % (in constant dollars).
    • Timberland® brand revenue five-year CAGR expected to up mid-single digit % (in constant dollars).
    • Dickies® brand revenue five-year CAGR expected to up high single digit % (in constant dollars).
    • Supreme® brand revenue five-year CAGR expected to up high single to low double-digit % (in constant dollars).
    • Outdoor emerging brands1 revenue five-year CAGR expected to up mid- to high teens % (in constant dollars).
  • Operating margin is expected to reach approximately 15% by FY27, representing a low double-digit 5-year operating profit CAGR (in constant dollars), driven by both gross margin expansion and SG&A leverage.
  • Tax rate is expected to be 17% to 18% in FY27, increasing gradually from approximately 16% in FY23.
  • EPS is expected to grow at a five-year CAGR of high-single to low double-digit % (in constant dollars), (vs FY22 adjusted EPS of $3.18).
  • Free cash flow2 generation is projected to be approximately $5.5 billion (cumulative from FY23 to FY27) with a total of approximately $7 billion in cash expected to be available to return to shareholders through dividends and share repurchases.
  • Organic TSR through FY27 is anticipated to grow at a five-year CAGR of between low double-digit and low teens %.

Q2’FY23 and FY23 Financial Outlook

  • Q2’FY23 revenue expected to be up low single digit % (in constant dollars) and adjusted EPS expected to be in the range of $0.70 to $0.75.
  • VF is revising its FY23 outlook due to lower-than-expected Q2’FY23 results, coupled with ongoing uncertainty in the current environment, weaker than anticipated back-to-school performance at Vans®and increasing inventories leading to a more promotional environment in North America in the fall; the revised outlook includes the following:

    • Total VF revenue is expected to be up about +5% to 6% (in constant dollars) versus previous outlook of at least +7%.

      • Vans® brand revenue is expected to be down mid-single digit % (in constant dollars) versus previous outlook of up mid-single digit %.
      • The North Face® brand revenue is expected to deliver at least low double-digit % growth (in constant dollars) versus previous outlook of up low double digit %.
    • Adjusted gross margin is expected to be down approximately 50 basis points versus previous outlook of up slightly.
    • Adjusted operating margin is expected to be approximately 12% versus previous outlook of approximately 13.2%.
    • Adjusted EPS is expected to be in the range of $2.60 to $2.70, versus $3.18 in the prior year and compared to previous outlook of $3.05 to $3.15.
    • Adjusted cash flow from operations of approximately $1.0 billion (versus previous outlook of approximately $1.2 billion) are anticipated; Capital expenditures expected to be approximately $240 million (versus previous outlook of approximately $250 million).
  • VF’s FY23 outlook assumes the following:

    • No additional significant COVID-19 related lockdowns in any key commercial or production regions.
    • No significant worsening in global inflation rates and consumer sentiment.

Supreme Impairment

The Company is testing the Supreme Trademark and Goodwill values during the second quarter due to a triggering event that is the result of higher interest rates and foreign currency fluctuations, which are expected to negatively affect the estimated fair values. As a result, and driven by these non-operating factors, the company expects to record a non-cash charge during Fiscal Q2 in the range of $300 million to $450 million.

Webcast Information

The event is being broadcast live via the internet, accessible at vfc.com/investor-day-2022 beginning at approximately 10:30am until 2:30pm ET today. An archived version will be available at the same location following the event.

Presentation

All presentations will be available at vfc.com/investor-day-2022 beginning at approximately 10:15am ET today and will be archived at the same location.

About VF

Founded in 1899, VF Corporation is one of the world’s largest active-lifestyle companies which connects people to the activities and experiences they cherish most through a portfolio of outdoor, active, workwear and streetwear brands including Vans®, The North Face®, Timberland® and Dickies®. Our purpose is to power movements of sustainable and active lifestyles for the betterment of people and our planet. We connect this purpose with a relentless drive to succeed to create value for all stakeholders and use our company as a force for good. For more information, please visit vfc.com.

Constant Currency – Excluding the Impact of Foreign Currency

This release refers to “reported” amounts in accordance with U.S. generally accepted accounting principles (“GAAP”), which include translation and transactional impacts from foreign currency exchange rates. This release also refers to “constant dollar” amounts, which exclude the impact of translating foreign currencies into U.S. dollars. Reconciliations of GAAP measures to constant currency amounts are presented in the supplemental financial information included with this release, which identifies and quantifies all excluded items, and provides management’s view of why this information is useful to investors.

The company also provides guidance on a non-GAAP basis as we cannot predict certain elements which are included in reported GAAP results, including the impact of foreign currency and other strategic initiatives. Additionally, the impact of the anticipated payment of taxes and interest related to the dispute previously disclosed with the IRS regarding the Timberland acquisition in 2011, has been excluded from FY23 adjusted cash flow from operations.

Forward-looking Statements

Certain statements included in this release are “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements are made based on our expectations and beliefs concerning future events impacting VF and therefore involve several risks and uncertainties. You can identify these statements by the fact that they use words such as “will,” “anticipate,” “estimate,” “expect,” “should,” and “may” and other words and terms of similar meaning or use of future dates, however, the absence of these words or similar expressions does not mean that a statement is not forward-looking. All statements regarding VF’s plans, objectives, projections and expectations relating to VF’s operations or financial performance, and assumptions related thereto are forward-looking statements. We caution that forward-looking statements are not guarantees and that actual results could differ materially from those expressed or implied in the forward-looking statements. VF undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Potential risks and uncertainties that could cause the actual results of operations or financial condition of VF to differ materially from those expressed or implied by forward-looking statements include, but are not limited to: risks arising from the widespread outbreak of an illness or any other communicable disease, or any other public health crisis, including the coronavirus (COVID-19) global pandemic; the level of consumer demand for apparel, footwear and accessories; disruption to VF’s distribution system; changes in global economic conditions and the financial strength of VF’s customers, including as a result of current inflationary pressures; fluctuations in the price, availability and quality of raw materials and contracted products; disruption and volatility in the global capital and credit markets; VF’s response to changing fashion trends, evolving consumer preferences and changing patterns of consumer behavior; intense competition from online retailers and other direct-to-consumer business risks; third-party manufacturing and product innovation; increasing pressure on margins; VF’s ability to implement its business strategy; VF’s ability to grow its international, direct-to-consumer and digital businesses; VF’s ability to transform its model to be more consumer-minded, retail-centric and hyper-digital; retail industry changes and challenges; VF’s ability to create and maintain an agile and efficient operating model and organizational structure; VF’s and its vendors’ ability to maintain the strength and security of information technology systems; the risk that VF’s facilities and systems and those of our third-party service providers may be vulnerable to and unable to anticipate or detect data or information security breaches and data or financial loss; VF’s ability to properly collect, use, manage and secure business, consumer and employee data and comply with privacy and security regulations; foreign currency fluctuations; stability of VF’s vendors’ manufacturing facilities and VF’s ability to establish and maintain effective supply chain capabilities; continued use by VF’s suppliers of ethical business practices; VF’s ability to accurately forecast demand for products; continuity of members of VF’s management; VF’s ability to recruit, develop or retain qualified employees; VF’s ability to protect trademarks and other intellectual property rights; possible goodwill and other asset impairment; maintenance by VF’s licensees and distributors of the value of VF’s brands; VF’s ability to execute acquisitions and dispositions and integrate acquisitions; business resiliency in response to natural or man-made economic, political or environmental disruptions; changes in tax laws and additional tax liabilities, including for the timing of income inclusion associated with our acquisition of the Timberland® brand in 2011; legal, regulatory, political, economic, and geopolitical risks, including those related to the current conflict in Ukraine; changes to laws and regulations; adverse or unexpected weather conditions; VF’s indebtedness and its ability to obtain financing on favorable terms, if needed, could prevent VF from fulfilling its financial obligations; climate change and increased focus on environmental, social and governance issues; and tax risks associated with the spin-off of our Jeanswear business completed in 2019. More information on potential factors that could affect VF’s financial results is included from time to time in VF’s public reports filed with the SEC, including VF’s Annual Report on Form 10-K, and Quarterly Reports on Form 10-Q, and Forms 8-K filed or furnished with the SEC.

_____________________________

1 Outdoor Emerging Brands defined as Altra, Smartwool® and Icebreaker®

2 Free Cash Flow defined as cash from operations less capital expenditures and software purchases

Investor Contact:

Allegra Perry

[email protected]

Media Contact:

Colin Wheeler

[email protected]

KEYWORDS: Colorado United States North America

INDUSTRY KEYWORDS: Fashion Consumer Retail Footwear Lifestyle

MEDIA:

Logo
Logo

Stanley Black & Decker Announces Release Date for Third Quarter 2022 Earnings

PR Newswire


NEW BRITAIN, Conn.
, Sept. 28, 2022 /PRNewswire/ — Stanley Black & Decker (NYSE: SWK) will broadcast its third quarter 2022 earnings webcast on Thursday, October 27, 2022. The webcast will begin at 8:00AM ET.

A news release outlining the financial results will be distributed before the market opens on Thursday, October 27, 2022. A slide presentation which will accompany the call will be available at www.stanleyblackanddecker.com/investors and will remain available after the call.

The call will be available through a live, listen-only webcast or teleconference.  Links to access the webcast, register for the teleconference, and view the accompanying slide presentation will be available on the “Investors” section of Stanley Black & Decker’s website, www.stanleyblackanddecker.com/investors under the subheading “News & Events.”  A replay will also be available two hours after the call and can be accessed on the “Investors” section of Stanley Black & Decker’s website.

Headquartered in the USA, Stanley Black & Decker (NYSE: SWK) is the world’s largest tool company operating nearly 50 manufacturing facilities across America and more than 100 worldwide. Guided by its purpose – for those who make the world – the company’s approximately 60,000 diverse and high-performing employees produce innovative, award-winning power tools, hand tools, storage, digital tool solutions, lifestyle products, outdoor products, engineered fasteners and other industrial equipment to support the world’s makers, creators, tradespeople and builders. The company’s iconic brands include DEWALT, BLACK+DECKER, CRAFTSMAN, STANLEY, CUB CADET, HUSTLER and TROY-BILT. Recognized for its leadership in environmental, social and governance (ESG), Stanley Black & Decker strives to be a force for good in support of its communities, employees, customers and other stakeholders. To learn more visit: www.stanleyblackanddecker.com.


Stanley Black & Decker Investor Contacts

Dennis Lange

Vice President, Investor Relations

(860) 827-3833

[email protected]

Cort Kaufman

Senior Director, Investor Relations

(860) 515-2741

[email protected]

Christina Francis

Director, Investor Relations

(860) 438-3470

[email protected]

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/stanley-black–decker-announces-release-date-for-third-quarter-2022-earnings-301635514.html

SOURCE Stanley Black & Decker

S&P Global Declares Fourth Quarter Dividend

PR Newswire


NEW YORK
, Sept. 28, 2022 /PRNewswire/ — The Board of Directors of S&P Global (NYSE: SPGI) has approved a cash dividend on the Corporation’s common stock for the fourth quarter of 2022. The dividend of $0.85 is payable on December 12, 2022, to shareholders of record on November 28, 2022. The annualized dividend rate is $3.40 per share.

The Company has paid a dividend each year since 1937 and is one of fewer than 25 companies in the S&P 500® that has increased its dividend annually for at least the last 49 years.

About S&P Global:

S&P Global (NYSE: SPGI) provides essential intelligence. We enable governments, businesses and individuals with the right data, expertise and connected technology so that they can make decisions with conviction. From helping our customers assess new investments to guiding them through ESG and energy transition across supply chains, we unlock new opportunities, solve challenges and accelerate progress for the world.

We are widely sought after by many of the world’s leading organizations to provide credit ratings, benchmarks, analytics and workflow solutions in the global capital, commodity and automotive markets. With every one of our offerings, we help the world’s leading organizations plan for tomorrow, today.

Contacts:

Investor Relations:

Mark Grant

Senior Vice President, Investor Relations
Tel:  + 1 347 640 1521

Media:

Christopher Krantz

Tel:  +44 7976 632 638
[email protected]

 

Cision View original content:https://www.prnewswire.com/news-releases/sp-global-declares-fourth-quarter-dividend-301635512.html

SOURCE S&P Global

Virtus Convertible & Income Fund, Virtus Convertible & Income Fund II Announce Tender Offers for Outstanding Auction Rate Preferred Shares

PR Newswire


HARTFORD, Conn.
, Sept. 28, 2022 /PRNewswire/ — Virtus Convertible & Income Fund (NCV) and Virtus Convertible & Income Fund II (NCZ) (each, a “Fund” and, together, the “Funds”), announced today that each Fund will commence a voluntary tender offer on or about September 30, 2022 (each, a “Tender Offer” and, together, the “Tender Offers”) for up to 100% of each Fund’s outstanding auction rate preferred shares (“ARPS”).  The Tender Offers are expected to expire at 5:00 p.m.New York City time on a date that is at least 20 business days following the commencement date. 

The terms of the Tender Offer for each Fund include the purchase, for cash, of up to 100% of the respective Fund’s issued and outstanding ARPS, at a price equal to 97.95% of the ARPS per share liquidation preference of $25,000 per share (or $24,487.50 per share), plus any unpaid ARPS dividends accrued through the expiration date of each Tender Offer, or such later date to which such Tender Offer may be extended.

This announcement is not a recommendation, an offer to purchase, or a solicitation of an offer to sell the ARPS of the Funds. The Funds will file with the Securities and Exchange Commission (“SEC”) a tender offer statement on Schedule TO and related exhibits, including an offer to purchase, and other related documents (the “Tender Offer Documents”). The Tender Offer Documents will be mailed or distributed electronically to ARPS holders commencing on or about September 30, 2022. These and other filed documents also will be available to ARPS holders free of charge on the SEC’s website and on each Fund’s page in the closed-end fund section of virtus.com. ARPS holders may obtain further information regarding the Tender Offers from Georgeson LLC, the Funds’ Depositary Agent and Information Agent for the Tender Offers, by calling (866) 785-7395 for NCV and (866) 857-2624 for NCZ.

About the Fund

Virtus Convertible & Income Fund and Virtus Convertible & Income Fund II each have an investment objective to provide total return through a combination of capital appreciation and high current income. Virtus Investment Advisers, Inc. is the investment adviser and Voya Investment Management is the subadviser to the Funds. For more information on the Funds, contact Shareholder Services at (866) 270-7788, by email at [email protected], or through the closed-end fund section of virtus.com.

Fund Risks

An investment in a fund is subject to risk, including the risk of possible loss of principal. A fund’s shares may be worth less upon their sale than what an investor paid for them. Shares of closed-end funds may trade at a premium or discount to their net asset value. For more information about the Funds’ investment objective and risks, please see the Funds’ annual report. A copy of the Funds’ most recent annual report may be obtained free of charge by contacting Shareholder Services as set forth at the bottom of this press release.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/virtus-convertible–income-fund-virtus-convertible–income-fund-ii-announce-tender-offers-for-outstanding-auction-rate-preferred-shares-301635508.html

SOURCE Virtus Convertible & Income Fund; Virtus Convertible & Income Fund II

CNS Pharmaceuticals Announces Activation of First Clinical Trial Sites in Europe for Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

PR Newswire

Sites in France and Spain now open and actively enrolling

Enrollment progressing with 26 clinical trial sites open to-date of the 59 sites
selected across the U.S., Italy, France, Spain, and Switzerland

Interim analysis of the trial when 30-50% of subjects reach 6 months in study


HOUSTON
, Sept. 28, 2022 /PRNewswire/ — CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the activation of its first clinical trial sites in Europe for the ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer. These first European clinical trial sites in France and Spain are now open and actively enrolling patients.

“Our primary focus continues to be on advancing the clinical development of Berubicin as a potential treatment option for this devastating disease. Over the course of this year, we have worked diligently to expand patient eligibility for our potentially pivotal trial and bolster our international presence now realized with the activation of the first two European clinical trial sites. This is a true testament to our team’s commitment to and the execution of this important clinical program. We are grateful for the tremendous support from the clinical staff and remain dedicated to driving patient enrollment as quickly and efficiently as possible. We look forward to continuing to build momentum and bringing Berubicin across the finish line to unlock its greatest potential. As long as the unmet medical need in GBM remains, we will continue our fight in earnest to bring hope to patients and families globally,” commented John Climaco, CEO of CNS Pharmaceuticals.

Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently being evaluated in a potentially pivotal global study evaluating its efficacy and safety in the treatment of GBM. The potentially pivotal trial is an adaptive, multicenter, open-label, randomized and controlled study in adult patients with recurrent glioblastoma multiforme (WHO Grade IV1) after failure of standard first-line therapy. The primary endpoint of the study is Overall Survival (OS), which is a rigorous endpoint that the FDA has recognized as a basis for approval of oncology drugs when a statistically significant improvement can be shown relative to a randomized control arm. Results from the trial will compare Berubicin to a current standard of care (Lomustine), with a 2 to 1 randomization of patients to receive either Berubicin or Lomustine. The recently amended protocol expands eligibility for the study to patients who have received additional treatments as part of the first line therapy for their disease considering advancements in this area. This change was made due to the complexity of new agents introduced as a component of first line therapy, which allows an additional group of patients that can enroll on the study after what may constitute multiple procedures as their initial treatment.

A pre-planned, non-binding futility analysis will be performed after approximately 30 to 50% of all planned patients have completed the primary endpoint at 6 months. This review will include additional evaluation of safety as well as secondary efficacy endpoints. Enrollment will not be paused during this interim analysis.

The FDA has granted CNS Pharmaceuticals Fast Track Designation for Berubicin which enables more frequent interactions with them to provide guidance on expediting the development and review process. Additionally, the Company has also received Orphan Drug Designation from the FDA which may provide seven years of marketing exclusivity upon approval of an NDA.


For more information about the potentially pivotal Berubicin trial, visit clinicaltrials.gov and reference identifier NCT04762069.

About Berubicin

 Berubicin is an anthracycline, a class of anticancer agents that are among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents. Anthracyclines are designed to utilize natural processes to induce deoxyribonucleic acid (DNA) damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation. Berubicin treatment of brain cancer patients appeared to demonstrate positive responses that include one durable complete response in a Phase 1 human clinical trial conducted by Reata Pharmaceuticals, Inc. Berubicin, was developed by Dr. Waldemar Priebe, Professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Center.

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.

Additionally, the Company is advancing the development of its WP1244 drug technology portfolio, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas.

For more information, please visit www.CNSPharma.com, and connect with the Company on Twitter, Facebook, and LinkedIn.

Forward-Looking Statements

Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of enrollment of new patients and the ability of the Company to complete the trial on a timely basis, if at all. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including ”believes,” ”estimates,” ”anticipates,” ”expects,” ”plans,” ”projects,” ”intends,” ”potential,” ”may,” ”could,” ”might,” ”will,” ”should,” ”approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including those discussed under Item 1A. “Risk Factors” in CNS’s most recently filed Form 10-K filed with the Securities and Exchange Commission (“SEC”) and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cns-pharmaceuticals-announces-activation-of-first-clinical-trial-sites-in-europe-for-ongoing-potentially-pivotal-global-trial-evaluating-berubicin-for-the-treatment-of-gbm-301634910.html

SOURCE CNS Pharmaceuticals, Inc.

The Vitamin Shoppe® Partners with Team RWB, America’s Leading Health and Wellness Community for Veterans, for the “WOD for Warriors” on Veterans Day 2022

PR Newswire

The Vitamin Shoppe
®
 and brand partners 1st Phorm
®
, BodyTech
®
, Cellucor
®
/C4
®
, Prime Hydration, and Redcon1® will donate $50,000 to support Team RWB’s mission to enrich the lives of military veterans


SECAUCUS, N.J.
, Sept. 28, 2022 /PRNewswire/ — The Vitamin Shoppe, an omnichannel specialty retailer of nutritional products, today announced its support and lead sponsorship of Team Red White & Blue’s (Team RWB) “WOD for Warriors,” a day of functional fitness on Veterans Day, November 11, 2022.

The WOD (Workout of the Day) sees thousands of veterans and their supporters complete a series of burpee box jumps, mountain climbers, and other exercises on Veterans Day, with sets and reps that symbolize and honor the men and women who have served our country. Participants can tackle the WOD either as an individual or with one of over 100 official host gyms across the country.

The annual event also supports Team RWB’s vision to forge America’s leading health and wellness community for veterans by offering real-life and virtual opportunities to build a healthier lifestyle.

The Vitamin Shoppe and its brand partners, including 1st Phorm, BodyTech, Cellucor/C4, Prime Hydration, and Redcon1, will donate $50,000 to Team RWB as lead sponsors of this year’s WOD for Warriors. Through November 11, every purchase of these brands at The Vitamin Shoppe and Super Supplements stores, as well as on www.vitaminshoppe.com, includes a $1 donation to that total contribution to support Team RWB and our nation’s veterans.

Additionally, from November 10 to 13, all veterans will receive a 25 percent discount on their entire purchase at any in-store location of The Vitamin Shoppe and Super Supplements.

Sharon Leite, CEO of The Vitamin Shoppe, commented: “Honoring veterans and supporting military families is a deeply important part of The Vitamin Shoppe’s commitment to our communities. Many of our own Health Enthusiast associates are veterans themselves, or have close ties to the military through family and friends, and I want to thank each of them for their service. All of us at The Vitamin Shoppe and Super Supplements are proud to have supported Team RWB’s work over the past years and I look forward to encouraging all of our customers to participate in this year’s WOD for Warriors. I also want to thank our incredible brand partners at 1st Phorm, BodyTech, Cellucor/C4, Prime Hydration, and Redcon1 for being an invaluable part of this campaign.”

Since 2020, The Vitamin Shoppe has supported Team RWB and raised over $135,000 for its impactful work forging the nation’s leading health and wellness community for veterans and their supporters.

“All of us at Team RWB are fired up to expand our partnership with The Vitamin Shoppe through WOD for Warriors this year,” said Mike Erwin, Executive Director of Team RWB. “The in-store, online, and event-based support The Vitamin Shoppe and its partner brands are offering as part of WOD for Warriors will inspire thousands of veterans and supporters to push themselves and honor those who served.”

As part of The Vitamin Shoppe’s support for the military and veteran community, on every Monday all current and former service members receive a 20 percent discount in-store at The Vitamin Shoppe and Super Supplements, by showing their valid military ID.

For more information about Team RWB or to register for this year’s WOD for Warriors, please visit www.teamrwb.org/w4w.

About The Vitamin Shoppe®

Lifelong Wellness Starts Here™. The Vitamin Shoppe®, a subsidiary of Franchise Group Inc. (NASDAQ: FRG), is a global, omnichannel specialty retailer and wellness lifestyle Company with the mission of providing customers with the most trusted products, guidance, and services to support them on their journeys of lifelong wellness. Based in Secaucus, New Jersey, the Company offers a comprehensive assortment of nutritional solutions, including vitamins, minerals, specialty supplements, herbs, sports nutrition, homeopathic remedies, green living products, and natural beauty products. In addition to carrying products from approximately 700 national brands, The Vitamin Shoppe offers products from its proprietary brands within its owned and wholesale channels, including: The Vitamin Shoppe®, Vthrive The Vitamin Shoppe™, BodyTech®, BodyTech® Elite, fitfactor™, fitfactor KETO™, plnt®, ProBioCare®, True Athlete®, and TrueYou™. In the U.S., the Company conducts business through over 700 company-operated retail stores under The Vitamin Shoppe and Super Supplements™ banners, and via its website, www.vitaminshoppe.com. The company is expanding its retail footprint via an innovative, omnichannel franchising model and opened its first franchise store in 2022. Globally, The Vitamin Shoppe serves customers in select Asia, South America, and Central America markets through local omnichannel partners.

About Team RWB

Team Red, White & Blue (Team RWB) is a nonprofit organization forging the nation’s leading health and wellness community. Founded in 2010, Team RWB supports veterans through their health and wellness journeys by offering real-life and virtual opportunities to build a healthier lifestyle. For more information about Team RWB and its 200,000 members visit teamrwb.org.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/the-vitamin-shoppe-partners-with-team-rwb-americas-leading-health-and-wellness-community-for-veterans-for-the-wod-for-warriors-on-veterans-day-2022-301635503.html

SOURCE The Vitamin Shoppe

Adeia Announces Executive Leadership Team and Board of Directors for Future Independent IP Licensing Business

Adeia Announces Executive Leadership Team and Board of Directors for Future Independent IP Licensing Business

SAN JOSE, Calif.–(BUSINESS WIRE)–
Adeia, the IP licensing business of Xperi Holding Corporation (NASDAQ: XPER) (the “Company”), today announced the appointment of both the leadership team and the Board of Directors of Adeia Inc., the future independent IP licensing business that will remain after the completion of the spin-off of the Company’s product business on October 1.

The new Adeia Inc. leadership team will be comprised of the following members:

  • Chief Executive Officer – Paul Davis
  • Chief Financial Officer – Keith Jones
  • Chief Legal Officer – Kevin Tanji
  • Chief Licensing Officer & General Manager, Media – Dr. Mark Kokes
  • Chief Licensing Officer & General Manager, Semiconductor – Dana Escobar
  • Chief People Officer – Denise Morgan

Paul Davis, Chief Executive Officer of Adeia, stated, “I am honored to begin our journey as a stand-alone company with a world class team that will continue our commitment to innovation. Adeia’s inventions will continue to help shape the way millions of people explore and experience entertainment and enhance billions of devices in an increasingly connected world. With decades of experience and one of the largest IP portfolios in the media and semiconductor industries, Adeia is exceptionally well positioned to continue its growth as a separate, publicly traded company.”

The Adeia Inc. Board of Directors will bring a strong combination of industry experience, corporate expertise, and diverse perspectives to Adeia Inc. The Board of Directors will be comprised of the following members:

  • Dan Moloney – Mr. Moloney will serve as the Chairman of Adeia Inc.’s Board of Directors. He has served as a member of Xperi Holding Corporation’s Board of Directors since June 2020 and served as a member of TiVo Corporation’s Board of Directors from September 2013 until June 2020. Mr. Moloney is an Executive Advisor at Siris Capital, LLC, a leading private equity firm in the technology and telecommunications industries. Mr. Moloney will also serve as Chair of the Adeia Inc.’s Compensation Committee.
  • Paul Davis – Mr. Davis was named Chief Executive Officer of Adeia Inc. effective upon completion of its separation as a stand-alone company on October 1. He is currently the Chief Legal Officer of Xperi Holding Corporation and President of the IP licensing business. He served as General Counsel and Corporate Secretary of Xperi Corporation, the predecessor to Xperi Holding Corporation, prior to the merger with TiVo Corporation in 2020 and as Senior Vice President, General Counsel and Corporate Secretary of Tessera Technologies, Inc., the predecessor to Xperi Corporation before the acquisition of DTS, Inc. in 2016.
  • V Sue Molina, CPA – Ms. Molina served as a member of Xperi Corporation’s Board of Directors from February 2018 to May 2020. She worked in public accounting for 27 years and was a Partner at both Ernst & Young and Deloitte. While at Deloitte she was the National Partner in charge of the Initiative for the Retention and Advancement of Women. Ms. Molina will also serve as Chair of Adeia Inc.’s Audit Committee.
  • Tonia O’Connor – Ms. O’Connor has served as a member of Xperi Holding Corporation’s Board of Directors since December 2021. She is the Chief Executive Officer of Tone It Up, a plant based, nutritional products company, for women, by women. Prior to joining Tone It Up, Ms. O’Connor was the Chief Executive Officer of Chopra Global and the President and Chief Revenue Officer of Univision Communications.
  • Raghavendra Rau – Mr. Rau has served as a member of Xperi Holding Corporation’s Board of Directors since June 2020. Prior to that Mr. Rau served as a member of TiVo Corporation’s Board of Directors since May 2015 and as Vice Chairman of the Board of Directors since June 2019. He was the interim President and Chief Executive Officer of TiVo Corporation from July 2018 to May 2019. Mr. Rau will also serve as Chair of Adeia Inc.’s Nominating and Corporate Governance Committee.

Paul Davis stated, “We are incredibly pleased to welcome each of these board members as we begin our journey as a stand-alone, publicly traded company. We look forward to benefitting from their expertise and valuable perspectives as we execute our long-term strategy.”

About Xperi Holding Corporation

Xperi invents, develops, and delivers technologies that enable extraordinary experiences. Xperi technologies, delivered via its brands (Adeia, DTS, HD Radio, IMAX Enhanced, TiVo), and by its startup, Perceive, make entertainment more entertaining, and smart devices smarter. Xperi technologies are integrated into billions of consumer devices, media platforms, and semiconductors worldwide, driving increased value for partners, customers and consumers.

Xperi, Adeia, DTS, IMAX Enhanced, HD Radio, Perceive, TiVo and their respective logos are trademarks or registered trademarks of affiliated companies of Xperi Holding Corporation in the United States and other countries. All other company, brand and product names may be trademarks or registered trademarks of their respective companies.

About Adeia

Adeia invents, develops and licenses fundamental innovations that shape the way millions of people explore and experience entertainment in an increasingly connected world. From TVs to smartphones, and across all types of entertainment experiences, Adeia’s technologies allow users to manage content and connections in a way that is smart, immersive and personal. For more information, please visit adeia.com.

Xperi Media:

Amy Brennan

[email protected]

Xperi Investors:

Jill Koval, Arbor Advisory Group

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Legal Technology Semiconductor Patent Law Other Technology Professional Services Software Audio/Video Hardware Consumer Electronics

MEDIA:

Global Average Annual Insured Losses from Extreme Events in Excess of $120 Billion, New Report from Verisk Finds

Analysis highlights key factors that contribute to increase in insured losses: the number and value of properties exposed to risk, natural variability when losses occur, climate change, and man-made loss drivers

BOSTON, Sept. 28, 2022 (GLOBE NEWSWIRE) — Today, Verisk Extreme Event Solutions released its 2022 Global Modeled Catastrophe Losses Report detailing key global financial loss metrics based on its latest suite of catastrophe models. Verisk (Nasdaq:VRSK) estimates that on an annual average basis, catastrophes around the world are expected to cause about $123 billion in insured losses compared to an average of $74 billion in actual losses over the past 10 years. This risk profile is assessed using Verisk’s global suite of models, which generate an industry exceedance probability (EP) curve that helps put years with high insured losses – like 2011 and 2017 – into context. 

“The most significant factor driving increased catastrophe losses over the past few years is the rise in exposure values and replacement costs,” said Bill Churney, president of Verisk Extreme Event Solutions. “Both are represented by continued construction in high-hazard areas as well as high levels of inflation that are driving up repair and rebuild costs. For this reason, it’s important for insurers to regularly reassess their exposures, particularly in the most vulnerable urban and coastal areas. Updating the property replacement values used in catastrophe modeling and other processes helps to ensure a more informed view of risk.” 

It is also important to consider the uncertainty and natural variability associated with global catastrophe losses. The current 5-year actual loss period has immediately followed a 10-year period of lower levels of loss highlighted by fewer loss-causing hurricanes in the Atlantic basin. Far larger years of insured losses can and will likely occur in today’s climatic conditions, and while climate change is contributing to increased catastrophe losses, it is to a lesser degree than the growth in the number and value of exposed properties.   

Verisk’s models estimate a more than 40% chance of experiencing a 5-year average loss in excess of $100B, meaning the last 5 years should not be viewed as out of the ordinary. Also, Verisk’s models show at least a 50% chance of experiencing a single year in the next decade with insured losses in excess of $200B.   

“All catastrophes can contribute to losses, whether they are a single major event, an aggregation of smaller ones, or a combination of the two. As demonstrated by this report, Verisk models are effectively capturing the scale of recent losses, but also indicate that years of more extreme losses are possible,” said Dr. Jayanta Guin, executive vice president and chief research officer of Verisk Extreme Event Solutions. “We continue to invest in catastrophe models that provide a global and comprehensive view of the complex nature of risk today and of the near-present climate.” 

The 2022 edition of the Global Modeled Catastrophe Losses report bases its global loss metrics on Verisk’s latest suite of catastrophe models, including updates released during 2022 and updated industry exposure databases (IEDs) around the world.  

Download the 2022Global Modeled Catastrophe Losses report here: https://bit.ly/GlobalEP2022 

About Extreme Event Solutions at Verisk  

Extreme event solutions at Verisk (AIR Worldwide) provides risk modeling solutions that help individuals, businesses, and society become more resilient to extreme events. In 1987, Verisk founded the catastrophe modeling industry and today models the risk from natural catastrophes, supply chain disruptions, terrorism, pandemics, and casualty catastrophes. Insurance, reinsurance, financial, corporate, and government clients rely on Verisk’s advanced science, software, and consulting services for catastrophe risk management, insurance-linked securities, longevity modeling, site-specific engineering analyses, and agricultural risk management. Verisk’s extreme event solutions team is headquartered in Boston, with additional offices in North America, Europe, and Asia. For more information, please visit www.air-worldwide.com. For more information about Verisk, a leading data analytics provider serving customers in insurance, energy and specialized markets, and financial services, please visit www.verisk.com.



Mary Keller 
Verisk Extreme Event Solutions 
617-267-6645 
[email protected]